Grapin C, Boyer C, Bruner M
Service de Chirurgie Viscérale Pédiatrique, Hôpital A.-Trousseau, Paris.
J Urol (Paris). 1994;100(1):8-16.
Tumours of the testicle are rare in children (about one case in 100,000 male children). Their histological type usually leads to favourable outcome. We report here our series of 12 cases together with an analysis of the large published series in order to review the prognosis and therapeutic indications which depend on the histology. The most frequent intratesticular tumours in the child are nonseminoma malignant germ cell tumours. At birth the tumour is usually a mature or mixed teratoma. Between the ages of 1 and 3 years the most frequently observed tumour arises from the vitelline sac representing about 50% of all tumours of the testicle in the child. From 3 years to puberty, paratesticular rhabdomyocarsomas and Leydig cell tumours are the most frequently encountered. Finally, at puberty, tumours of the testicle are the same as those observed in the adult, notably seminomas which are not observed before puberty. Other tumours occur only exceptionally. Orchiectomy after ligature of the spermatic cord is the usual treatment. Complementary chemotherapy and node dissection are not required as first intention therapy when the tumour is well localized (complete exeresis, no lymph node invasion, no pulmonary metastasis), but are reserved for relapse or residual tumours revealed by a secondary rise in alpha foetoprotein levels or by extension from the initial site. A present, in 80% of the patients with localized tumours, outcome is favourable without lymph node dissection or chemotherapy. The three-year survival rate is approximately 90%.
睾丸肿瘤在儿童中较为罕见(约每10万名男童中有1例)。其组织学类型通常预后良好。我们在此报告我们的12例病例系列,并分析大量已发表的系列病例,以回顾取决于组织学的预后和治疗指征。儿童最常见的睾丸内肿瘤是非精原细胞瘤性恶性生殖细胞肿瘤。出生时肿瘤通常是成熟型或混合型畸胎瘤。1至3岁之间,最常观察到的肿瘤起源于卵黄囊,约占儿童所有睾丸肿瘤的50%。3岁至青春期,睾丸旁横纹肌肉瘤和间质细胞瘤最为常见。最后,在青春期,睾丸肿瘤与成人所见的相同,尤其是精原细胞瘤在青春期前未观察到。其他肿瘤仅偶尔发生。通常治疗方法是结扎精索后进行睾丸切除术。当肿瘤定位良好(完整切除、无淋巴结侵犯、无肺转移)时,初次治疗不需要辅助化疗和淋巴结清扫,但保留用于复发或因甲胎蛋白水平二次升高或初始部位扩展而发现的残留肿瘤。目前,80%局限性肿瘤患者未经淋巴结清扫或化疗预后良好。三年生存率约为90%。